amiodarone has been researched along with Chronic Kidney Failure in 17 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Poisoning with flecainide acetate is rare and associated with a high mortality." | 8.80 | [Severe flecainide acetate poisoning. Apropos of a case]. ( Chevrolet, JC; Elamly, A; Maury, P; Metzger, J; Schoenenberger, I; Veragut, B; Vuille, C, 1999) |
| " Laboratory studies revealed cardiogenic ascites coincided with nephrogenic ascites and subclinical amiodarone-induced hypothyroidism." | 7.78 | Development of refractory ascites during amiodarone therapy in a hemodialysis patient with nephrogenic and cardiogenic ascites. ( Chen, JD; Hwang, B; Lin, YF; Wang, JY, 2012) |
| " After administration of atorvastatin, amiodarone, and fluconazole, rhabdomyolysis developed with electrolyte disturbances (hyperphosphatemia, hyopcalcemia) and a massive increase in creatine kinase and myoglobin." | 7.77 | [Rhabdomyolysis associated with atorvastatin combined with amiodarone and fluconazole]. ( Bruggisser, M; Franz, CC; Krähenbühl, S; Rätz Bravo, AE, 2011) |
| "Here, we report a patient with chronic renal failure who developed EPO-resistant anemia after amiodarone treatment for arrhythmia." | 5.35 | Amiodarone-induced hypothyroidism with EPO-resistant anemia in a patient with chronic renal failure. ( Chang, PM; Ng, YY, 2008) |
| "Poisoning with flecainide acetate is rare and associated with a high mortality." | 4.80 | [Severe flecainide acetate poisoning. Apropos of a case]. ( Chevrolet, JC; Elamly, A; Maury, P; Metzger, J; Schoenenberger, I; Veragut, B; Vuille, C, 1999) |
| " The study revealed hypothyroidism, iatrogenic due to the use of amiodarone." | 3.96 | An unexpected cause of residual renal function loss. ( Abrantes, C; Assunção, J; Furtado, T; Soares, E; Valério, P; Vaz, AG, 2020) |
| " Here, we present the HCV treatment challenges facing a patient with HIV coinfection, prior failure of both HIV-1 and HCV therapy, cirrhosis, end-stage renal failure on haemodialysis, as well as management of drug-drug interactions, especially given the need to receive long-term amiodarone therapy." | 3.88 | Cure of chronic hepatitis C virus infection in an HIV-coinfected patient with multiple comorbidities and drug interaction challenges. ( Álvarez, H; Bhagani, S; Khoo, S; Llibre, JM; Mariño, A; Schapiro, J; Valcarce, N, 2018) |
| " Laboratory studies revealed cardiogenic ascites coincided with nephrogenic ascites and subclinical amiodarone-induced hypothyroidism." | 3.78 | Development of refractory ascites during amiodarone therapy in a hemodialysis patient with nephrogenic and cardiogenic ascites. ( Chen, JD; Hwang, B; Lin, YF; Wang, JY, 2012) |
| " After administration of atorvastatin, amiodarone, and fluconazole, rhabdomyolysis developed with electrolyte disturbances (hyperphosphatemia, hyopcalcemia) and a massive increase in creatine kinase and myoglobin." | 3.77 | [Rhabdomyolysis associated with atorvastatin combined with amiodarone and fluconazole]. ( Bruggisser, M; Franz, CC; Krähenbühl, S; Rätz Bravo, AE, 2011) |
| " We evaluated the clinical performance of nine FT4 assays in five centres, using a panel of 310 sera: 156 from euthyroid controls; 27 from hyperthyroid patients; 34 from untreated hypothyroidism; 22 from patients with renal failure; 30 from women in the last trimester of pregnancy; 23 from patients on thyroid substitutive therapy; and 18 from patients treated with amiodarone." | 3.72 | Clinical evaluation of nine free thyroxine assays: persistent problems in particular populations. ( Beaudonnet, A; d'Herbomez, M; Forzy, G; Gasser, F; Massart, C; Sapin, R, 2003) |
| "Three labeled-antibody immunoassays of free triiodothyronine (FT3) were studied in hyperthyroid patients, patients with nonthyroidal illness, and patients being treated with amiodarone; we also studied sera presenting known interferences (n for all groups = 465)." | 3.69 | Clinical comparison of three labeled-antibody immunoassays of free triiodothyronine. ( Cosson, E; d'Herbomez, M; Dilouya, A; Dumont, A; Helal, BO; Le Guillouzic, D; Lebtahi, R; Piketty, ML, 1996) |
| "Two patients in chronic renal failure receiving amiodarone for the treatment of refractory arrhythmias were commenced on dialysis, in one case, intermittent peritoneal dialysis, in the other, haemodialysis." | 3.66 | Renal elimination of amiodarone and its desethyl metabolite. ( Harris, L; Hind, CR; Holt, DW; Krikler, SJ; McKenna, WJ; Savage, C; Storey, GC, 1983) |
| "Here, we report a patient with chronic renal failure who developed EPO-resistant anemia after amiodarone treatment for arrhythmia." | 1.35 | Amiodarone-induced hypothyroidism with EPO-resistant anemia in a patient with chronic renal failure. ( Chang, PM; Ng, YY, 2008) |
| "Amiodarone is a very effective antiarrhytmic drug." | 1.34 | Hyperglobulinemia in amiodarone-induced pneumonitis. ( Antipov, N; Farfel, Z; Mayan, H; Mouallem, M; Sela, BA, 2007) |
| " Thus, dosage adjustment in patients with renal impairment is not necessary based on this pharmacokinetic analysis." | 1.29 | Disposition of intravenous amiodarone in subjects with normal and impaired renal function. ( Chow, MS; Izard, M; Klamerus, KJ; Neefe, DL; O'Rangers, E; Ujhelyi, MR; Vadiei, K; Zimmerman, JJ, 1996) |
| " Pharmacokinetic parameters were derived from plasma samples obtained over a 24-h period." | 1.27 | Effect of renal failure or biliary stasis on the pharmacokinetics of amiodarone in the rat. ( Bernhard, R; Ferguson, RK; Fruncillo, RJ; Marchion, C; Swanson, BN, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (23.53) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Soares, E | 1 |
| Valério, P | 1 |
| Abrantes, C | 1 |
| Furtado, T | 1 |
| Assunção, J | 1 |
| Vaz, AG | 1 |
| Torimitsu, T | 1 |
| Yoshida, T | 1 |
| Nishi, S | 1 |
| Itoh, H | 1 |
| Oya, M | 1 |
| Álvarez, H | 1 |
| Mariño, A | 1 |
| Valcarce, N | 1 |
| Khoo, S | 1 |
| Bhagani, S | 1 |
| Schapiro, J | 1 |
| Llibre, JM | 1 |
| Chang, PM | 1 |
| Ng, YY | 1 |
| González Oliva, JC | 1 |
| Saurina i Solé, A | 1 |
| Pou Potau, M | 1 |
| Salas Gama, KR | 1 |
| Ramírez de Arellano Serna, M | 1 |
| Burger, CI | 1 |
| Clase, CM | 1 |
| Gangji, AS | 1 |
| Franz, CC | 1 |
| Bruggisser, M | 1 |
| Krähenbühl, S | 1 |
| Rätz Bravo, AE | 1 |
| Wang, JY | 1 |
| Hwang, B | 1 |
| Lin, YF | 1 |
| Chen, JD | 1 |
| d'Herbomez, M | 2 |
| Forzy, G | 1 |
| Gasser, F | 1 |
| Massart, C | 1 |
| Beaudonnet, A | 1 |
| Sapin, R | 1 |
| Mouallem, M | 1 |
| Antipov, N | 1 |
| Mayan, H | 1 |
| Sela, BA | 1 |
| Farfel, Z | 1 |
| Harris, L | 1 |
| Hind, CR | 1 |
| McKenna, WJ | 1 |
| Savage, C | 1 |
| Krikler, SJ | 1 |
| Storey, GC | 1 |
| Holt, DW | 1 |
| Bonati, M | 1 |
| Galletti, F | 1 |
| Volpi, A | 1 |
| Cumetti, C | 1 |
| Rumolo, R | 1 |
| Bassini, O | 1 |
| Tognoni, G | 1 |
| Piketty, ML | 1 |
| Le Guillouzic, D | 1 |
| Lebtahi, R | 1 |
| Cosson, E | 1 |
| Dumont, A | 1 |
| Dilouya, A | 1 |
| Helal, BO | 1 |
| Ujhelyi, MR | 1 |
| Klamerus, KJ | 1 |
| Vadiei, K | 1 |
| O'Rangers, E | 1 |
| Izard, M | 1 |
| Neefe, DL | 1 |
| Zimmerman, JJ | 1 |
| Chow, MS | 1 |
| Maury, P | 1 |
| Vuille, C | 1 |
| Metzger, J | 1 |
| Veragut, B | 1 |
| Schoenenberger, I | 1 |
| Elamly, A | 1 |
| Chevrolet, JC | 1 |
| Koren, G | 1 |
| Parker, R | 1 |
| Fruncillo, RJ | 1 |
| Swanson, BN | 1 |
| Bernhard, R | 1 |
| Marchion, C | 1 |
| Ferguson, RK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients With Atrial Tachyarrhythmias[NCT03413150] | 80 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for amiodarone and Chronic Kidney Failure
| Article | Year |
|---|---|
[Severe flecainide acetate poisoning. Apropos of a case].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Biological Availability; Calcium Gluconate | 1999 |
16 other studies available for amiodarone and Chronic Kidney Failure
| Article | Year |
|---|---|
An unexpected cause of residual renal function loss.
Topics: Amiodarone; Disease Progression; Glomerular Filtration Rate; Humans; Hypothyroidism; Kidney Failure, | 2020 |
Amiodarone-induced multiple organ damage in an Alström syndrome patient with end-stage renal disease and hepatic cirrhosis.
Topics: Alstrom Syndrome; Amiodarone; Cardiomyopathy, Dilated; Diabetes Mellitus, Type 2; Female; Humans; Ki | 2022 |
Cure of chronic hepatitis C virus infection in an HIV-coinfected patient with multiple comorbidities and drug interaction challenges.
Topics: Amiodarone; Antiviral Agents; Coinfection; Comorbidity; Drug Interactions; Female; Heart Diseases; H | 2018 |
Amiodarone-induced hypothyroidism with EPO-resistant anemia in a patient with chronic renal failure.
Topics: Aged, 80 and over; Amiodarone; Anemia; Anti-Arrhythmia Agents; Drug Resistance; Erythropoietin; Huma | 2008 |
[Difficult-to-treat atrial fibrillation in a patient on haemodialysis].
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Atrial Fibrillation; Bisoprolol; Bradycardia; Calcium | 2010 |
Case report: drug interaction between tacrolimus and amiodarone with QT prolongation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Diabetic Neph | 2010 |
[Rhabdomyolysis associated with atorvastatin combined with amiodarone and fluconazole].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticholesteremic Agents; Antifungal Agents; Atorvastatin; | 2011 |
Development of refractory ascites during amiodarone therapy in a hemodialysis patient with nephrogenic and cardiogenic ascites.
Topics: Aged; Amiodarone; Ascites; Female; Heart Failure; Humans; Hypothyroidism; Kidney Failure, Chronic; P | 2012 |
Clinical evaluation of nine free thyroxine assays: persistent problems in particular populations.
Topics: Amiodarone; Anti-Arrhythmia Agents; Blood Chemical Analysis; Female; Humans; Hyperthyroidism; Kidney | 2003 |
Hyperglobulinemia in amiodarone-induced pneumonitis.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Coronary Artery Disease; Female; Humans | 2007 |
Renal elimination of amiodarone and its desethyl metabolite.
Topics: Amiodarone; Arrhythmias, Cardiac; Benzofurans; Female; Humans; Kidney; Kidney Failure, Chronic; Male | 1983 |
Amiodarone in patients on long-term dialysis.
Topics: Adult; Aged; Amiodarone; Benzofurans; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Re | 1983 |
Clinical comparison of three labeled-antibody immunoassays of free triiodothyronine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Autoanalysis; Autoantibodies; Humans; Hypert | 1996 |
Disposition of intravenous amiodarone in subjects with normal and impaired renal function.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Female; Glomerular Filtration Rate; Humans; Infusio | 1996 |
Interpretation of excessive serum concentrations of digoxin in children.
Topics: Adolescent; Amiodarone; Blood Proteins; Cardenolides; Digoxin; Drug Interactions; Female; Half-Life; | 1985 |
Effect of renal failure or biliary stasis on the pharmacokinetics of amiodarone in the rat.
Topics: Amiodarone; Animals; Benzofurans; Cholestasis; Dealkylation; Glucuronates; Kidney Failure, Chronic; | 1986 |